ClinicalTrials.gg
Not yet recruitingNCT07472387Andro-iGlioUpdated Mar 16, 2026

Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas

An interventional study of blood sampling and saliva sampling in Glioblastoma (GBM), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris — 2 open to participants now, 2 under way, none of them phase 3. Glioblastoma · Assistance Publique - Hôpitaux de Paris.

Started
2026
the only one that year
No phase
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2026, is the only one with no phase, and was the 11th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

2 of the 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Glioblastoma (GBM) is the most common and most aggressive primary brain cancer in adults. GBM is more common in men than in women, with a male-to-female ratio of 1.6. Furthermore, being male is associated with a poorer prognosis. These data suggest that sex and/or sexual hormones and more specifically androgens may play a role in the initiation, the growth, and the resistance to treatments of GBM.

Read the detailed description

Glioblastoma (GBM) is the most common and most aggressive primary brain tumor in adults, with an annual incidence in France of approximately 2,500-3,500 new cases. Despite intensive multimodal treatment, the median overall survival remains less than 18 months.

For reasons that are not yet fully understood, GBM occurs more frequently in men than in women, with a male-to-female ratio of approximately 1.6. Moreover, male sex appears to be associated with a poorer prognosis, as men diagnosed with GBM tend to have shorter survival compared with women. Importantly, such sex-based differences are not restricted to GBM; with few exceptions, they are also observed in most non-hormone-dependent systemic cancers.

These epidemiological and clinical observations suggest that sex and/or sex steroid hormones-particularly androgens-may contribute to GBM biology. The effects of androgens are primarily mediated through their binding to the androgen receptor (AR). Preliminary data indicate that AR is expressed not only by GBM tumor cells but also by cells within the tumor microenvironment, especially cells of the myeloid lineage, including microglia and tumor-associated macrophages.

In addition, some studies have shown that certain GBM cells are capable of producing dihydrotestosterone. Taken together, these findings support a potential role for androgen signaling in modulating both tumor cells and the immune microenvironment in GBM. They also provide a rationale for evaluating anti-androgen therapies, either alone or in combination with other treatment modalities, including immunotherapies, in patients with GBM.

Further support for this hypothesis comes from studies in systemic cancers. In prostate cancer, for example, anti-androgen therapy has been shown to increase cytotoxic T lymphocyte infiltration. Combinations of hormone therapy and immunotherapy have been tested in preclinical models, demonstrating reduced androgen-induced immunosuppression and enhanced sensitivity to immune checkpoint inhibitors, an approach currently being explored in clinical trials. Moreover, in melanoma-a non-hormone-dependent cancer such as GBM-AR silencing increases cytotoxic T-cell infiltration, reduces regulatory T-cell infiltration, and decreases the expression of immune inhibitory molecules such as LAG-3 and PD-1.

03

Conditions studied

  • Glioblastoma (GBM)

Browse trials for

Keywords

  • Glioblastoma
  • Androgen
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥18 and ≤55
  • Newly diagnosed GBM
  • Surgery with complete or incomplete resection
  • Eligible for chemoradiotherapy
  • No active immune disorders
  • Supratentorial location on MRI and no signs of meningeal dissemination
  • Tumor sample (taken as part of treatment) available for study (fresh frozen tissue)
  • Patient informed and consented to participate in the study
  • Affiliation with a social security system or beneficiary

Exclusion criteria

Exclusion Criteria:

  • Active infection at the time of sampling or within the previous 14 days
  • Active immune disorders
  • Known patients with low-grade glioma that has undergone anaplastic transformation
  • Patients treated with
  • Patients participating in interventional research
  • Patients under legal protection, guardianship, or conservatorship.
  • Pregnant or breastfeeding women
  • Individuals under AME
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Glioblastoma patients

    Adult men and women with GBM who are being treated in the neuro-oncology department at La Pitié-Salpêtrière Hospital.

    Other: blood sampling · Other: saliva sampling · Other: stool sampling · Other: Tumor sampling

Interventions

  • Otherblood sampling

    Additional blood samples (in addition to those taken as part of treatment) will be taken from patients at T1 (before any medical treatment) and at T2 (one month after the end of concomitant chemoradiotherapy). These samples, totaling 6 to 8 mL, will be taken between 9 a.m. and 11 a.m. (this time slot allows patients to normalize their circadian rhythm)

  • Othersaliva sampling

    During these same visits at T1 and T2, a saliva sample will be collected using Salivette® Cortisol saliva collection devices (UGAP ref.: 2745674)

  • Otherstool sampling

    During these same visits at T1 and T2, a stool sample will be collected by the patient using the kit (Stool Sample Collection Kit with Stool Catcher, Canvax)

  • OtherTumor sampling

    At the time of surgery performed as part of treatment (before T1), tumor tissue from the surgical waste will be collected.

06

What researchers measure

Primary outcomes

  1. Mean expression of AR, ER, and other hormone signaling pathway genes in the tumor

    Expression of AR, ER, and other hormone signaling pathway genes using tumor RNA sequencing data

    Time frame: Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy

Secondary outcomes

  1. Mean of Percentage of immunosuppressive cells measured at T1 and T2 in the blood and tumor

    Percentage of immunosuppressive cells measured at T1 and T2 in the blood and tumor using spectral cytometry

    Time frame: Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy

  2. Profile of immunosuppressive cytokines in the tumor

    Profile of immunosuppressive cytokines in the tumor (quantification of a panel of cytokines)

    Time frame: Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy

  3. Mean of the Proportion of intratumoral immune cells

    Proportion of intratumoral immune cells via the deconvolution of tumor RNA sequencing data

    Time frame: Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy

07

Study locations

1 site
  • Neuro-oncology department, Pitié Salpêtrière hospital
    Paris, 75013, France
08

References and documents

Individual participant data

Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2030, 48 months later.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 48 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Mar 16, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Apr 1, 2030
CompletionEst.
Apr 1, 2030
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07472387
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Apr 1, 2030 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Mar 16, 2026

Study contacts

Ahmed IDBAIH, MD-PhD
Contact
ahmed.idbaih@aphp.fr
01 42 16 03 85 ext. +33
Maïté VERREAULT, PhD
Contact
maite.verreault@icm-institute.org
01 57 27 43 91 ext. +33
Ahmed IDBAIH, MD-PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion